Literature DB >> 2024511

Overview of osteoporosis.

B L Riggs1.   

Abstract

Osteoporosis is a common age-related disorder manifested clinically by skeletal fractures, especially fractures of the vertebrae, hip, and distal forearm. The major cause of these fractures is low bone mass, although an increase in trauma due to falls in the elderly also contributes. There are multiple causes for the low bone mass which, in any given individual, may contribute differently to the development of the osteopenia. The most important groups of causes are failure to achieve adequate peak bone mass, slow bone loss due to processes relating to aging, the menopause in women, and a variety of sporadic behavioral, nutritional, and environmental factors that affect bone mass in some but not in other individuals. The most important approach is prevention. Drugs and behavioral factors known to cause bone loss should be eliminated and perimenopausal women should be evaluated for possible preventive administration of estrogen. For patients with fractures due to established osteoporosis, the only drugs approved by the Food and Drug Administration are the antiresorptive agents calcium, estrogen, and calcitonin. Formation-stimulating regimens, however, are being developed and may be available for clinical use in the foreseeable future. These regimens may be capable of increasing bone mass to above the fracture threshold, thereby resulting in a clinical cure of the osteoporosis.

Entities:  

Mesh:

Year:  1991        PMID: 2024511      PMCID: PMC1002677     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  78 in total

1.  The influence of age on bone mineral regulating hormones.

Authors:  S Epstein; G Bryce; J W Hinman; O N Miller; B L Riggs; S L Hui; C C Johnston
Journal:  Bone       Date:  1986       Impact factor: 4.398

2.  Evidence for two distinct syndromes of involutional osteoporosis.

Authors:  B L Riggs; L J Melton
Journal:  Am J Med       Date:  1983-12       Impact factor: 4.965

3.  Relative contributions of aging and estrogen deficiency to postmenopausal bone loss.

Authors:  L S Richelson; H W Wahner; L J Melton; B L Riggs
Journal:  N Engl J Med       Date:  1984-11-15       Impact factor: 91.245

4.  Estrogen replacement therapy: indications and complications.

Authors:  H L Judd; D R Meldrum; L J Deftos; B E Henderson
Journal:  Ann Intern Med       Date:  1983-02       Impact factor: 25.391

5.  Estrogen therapy arrests bone loss in elderly women.

Authors:  M E Quigley; P L Martin; A M Burnier; P Brooks
Journal:  Am J Obstet Gynecol       Date:  1987-06       Impact factor: 8.661

6.  Risk factors for spinal osteoporosis in men.

Authors:  E Seeman; L J Melton; W M O'Fallon; B L Riggs
Journal:  Am J Med       Date:  1983-12       Impact factor: 4.965

7.  Osteoporosis and decline of gonadal function in the elderly male.

Authors:  C Foresta; G Ruzza; R Mioni; G Guarneri; R Gribaldo; A Meneghello; I Mastrogiacomo
Journal:  Horm Res       Date:  1984

8.  Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss.

Authors:  A M Parfitt; C H Mathews; A R Villanueva; M Kleerekoper; B Frame; D S Rao
Journal:  J Clin Invest       Date:  1983-10       Impact factor: 14.808

Review 9.  Vitamin D and bone health in the elderly.

Authors:  A M Parfitt; J C Gallagher; R P Heaney; C C Johnston; R Neer; G D Whedon
Journal:  Am J Clin Nutr       Date:  1982-11       Impact factor: 7.045

10.  Stanozolol in postmenopausal osteoporosis: therapeutic efficacy and possible mechanisms of action.

Authors:  C H Chesnut; J L Ivey; H E Gruber; M Matthews; W B Nelp; K Sisom; D J Baylink
Journal:  Metabolism       Date:  1983-06       Impact factor: 8.694

View more
  23 in total

Review 1.  Osteoporosis: clinical features, prevention, and treatment.

Authors:  L A Fleming
Journal:  J Gen Intern Med       Date:  1992 Sep-Oct       Impact factor: 5.128

Review 2.  Selective estrogen receptor modulators.

Authors:  Henry U Bryant
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

3.  Osteoporosis at the end of the century.

Authors:  R P Heaney
Journal:  West J Med       Date:  1991-01

4.  Risk for osteoporosis in black women.

Authors:  J F Aloia; A Vaswani; J K Yeh; E Flaster
Journal:  Calcif Tissue Int       Date:  1996-12       Impact factor: 4.333

5.  Age-related changes in trabecular bone microstructures: global and local morphometry.

Authors:  M Stauber; R Müller
Journal:  Osteoporos Int       Date:  2005-12-31       Impact factor: 4.507

6.  New biocomposite [biphasic calcium phosphate/ poly-DL-lactide-co-glycolide/biostimulative agent] filler for reconstruction of bone tissue changed by osteoporosis.

Authors:  N Ignjatovic; Z Ajdukovic; D Uskokovic
Journal:  J Mater Sci Mater Med       Date:  2005-07       Impact factor: 3.896

7.  Inhibition of Sca-1-positive skeletal stem cell recruitment by alendronate blunts the anabolic effects of parathyroid hormone on bone remodeling.

Authors:  Xiangwei Wu; Lijuan Pang; Weiqi Lei; William Lu; Jun Li; Zhaoyang Li; Frank J Frassica; Xueling Chen; Mei Wan; Xu Cao
Journal:  Cell Stem Cell       Date:  2010-11-05       Impact factor: 24.633

8.  Hyperostosis frontalis interna (HFI) and castration: the case of the famous singer Farinelli (1705-1782).

Authors:  Maria Giovanna Belcastro; Antonio Todero; Gino Fornaciari; Valentina Mariotti
Journal:  J Anat       Date:  2011-07-11       Impact factor: 2.610

9.  Coincidence of calcified carotid atheromatous plaque, osteoporosis, and periodontal bone loss in dental panoramic radiographs.

Authors:  Aruna Ramesh; Sheila Soroushian; Rumpa Ganguly
Journal:  Imaging Sci Dent       Date:  2013-12-12

10.  Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.

Authors:  L J Black; M Sato; E R Rowley; D E Magee; A Bekele; D C Williams; G J Cullinan; R Bendele; R F Kauffman; W R Bensch
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.